Diploma (LON:DPLM) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Diploma (LON:DPLM) had its price objective increased by equities researchers at Berenberg Bank from GBX 6,600 to GBX 7,500 in a report released on Thursday,London Stock Exchange reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 29.42% from the stock’s previous close.

DPLM has been the subject of several other research reports. Stifel Nicolaus raised their price objective on shares of Diploma from GBX 6,200 to GBX 6,800 and gave the stock a “buy” rating in a research note on Thursday. Peel Hunt reiterated a “buy” rating and issued a GBX 6,150 price target on shares of Diploma in a report on Friday, December 19th. Royal Bank Of Canada raised their price target on Diploma from GBX 6,200 to GBX 6,600 and gave the stock an “outperform” rating in a research note on Thursday. Shore Capital Group restated a “hold” rating on shares of Diploma in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Diploma from GBX 6,200 to GBX 6,400 and gave the company a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Diploma has an average rating of “Moderate Buy” and an average price target of GBX 6,023.75.

Diploma Trading Down 2.2%

Shares of DPLM stock traded down GBX 130 during trading hours on Thursday, reaching GBX 5,795. 38,388,117 shares of the stock were exchanged, compared to its average volume of 2,353,902. Diploma has a 12-month low of GBX 3,532 and a 12-month high of GBX 6,019.52. The company has a current ratio of 2.04, a quick ratio of 0.80 and a debt-to-equity ratio of 46.97. The company’s 50-day moving average price is GBX 5,451.05 and its 200-day moving average price is GBX 5,421.27. The firm has a market capitalization of £7.77 billion, a price-to-earnings ratio of 42.21, a price-to-earnings-growth ratio of 2.82 and a beta of 1.03.

Insider Transactions at Diploma

In other Diploma news, insider Johnny Thomson sold 30,000 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of GBX 5,668, for a total transaction of £1,700,400. Also, insider Katie Bickerstaffe bought 352 shares of the firm’s stock in a transaction on Wednesday, January 14th. The shares were purchased at an average cost of GBX 5,645 per share, with a total value of £19,870.40. Insiders purchased 1,262 shares of company stock worth $6,995,830 in the last ninety days. 1.14% of the stock is owned by company insiders.

More Diploma News

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Management upgraded FY2026 guidance after a strong first half — the outlook upgrade was described as “significant” and cited resilient aerospace demand as a driver. Read More.
• Positive Sentiment: Market reaction: several outlets report shares surged (up as much as ~17%) after the profit/guidance upgrade, showing the news materially raised investor expectations. Read More.
• Positive Sentiment: Analyst actions: Royal Bank of Canada raised its price target from 6,200p to 6,600p and moved to an “Outperform” rating. Read More., Read More.
• Positive Sentiment: Analyst actions: Stifel Nicolaus lifted its target from 6,200p to 6,800p and put a “Buy” on the stock — adding upward pressure on valuation. Read More.
• Neutral Sentiment: Some brokers remain cautious: Shore Capital reaffirmed a “Hold” rating, tempering unanimity of the buy-side upgrades. Read More., Read More.
• Negative Sentiment: Intraday selling/profit‑taking: after the sharp rally on guidance and upgraded forecasts, the stock pulled back amid very heavy volume (well above average), suggesting short‑term profit taking and volatility even though the fundamental outlook was upgraded. Read More.

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.